Parkinson’s Disease Therapeutics to Exceed $4.6 billion revenue by 2012, says New Report

PRLog (Press Release) - Apr 11, 2008 -
Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report showing that the revenues of Parkinson’s Disease (PD) therapeutics across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $2.2bn in 2006, with revenues expected to exceed $4.6bn by 2012. In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005.

“Parkinson's Disease Market analysis and forecasts”, which is available at http://www.reportbuyer.com/go/VIS00056, reports that PD is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.

The report analysis PD sales over the next 15 years and delivers the percentage market growth. The projected revenue growth will be driven largely by reformulations that will decrease the burden of polypharmacy in patients receiving PD pharmacotherapy. The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline's (GSK's) Requip Once-daily ER awaiting approval, UCB-Schwarz's Neupro, Teva and Lundbeck's Azilect.

Other key compounds predicted for success include Kyowa Hakko's Istradefylline, Merck-Serono/Newron's Safinamide. The new wave of Gene/cell Therapy compounds that have revealed positive initial clinical data, thus Neurotrophic growth factors (NGF), either to be injected directly into the brain are also tipped for potential market success. Ceregene's Neuturine, Neurologix' GAD (glutamic acid decarboxylase) amongst other similar drugs, will add to the present PD therapeutics that will expand revenue growth in the long-term.

“Parkinson's Disease Market analysis and forecasts” is available from Report Buyer. For more information go to:   http://www.reportbuyer.com/pharma_healthcare/diseases/par...

Report Buyer product ID: VIS00056

Photo:
http://www.prlog.org/10063055/1